Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Firestein

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Biochimica Et Biophysica Acta|April 15, 2009
Integrative genomic approaches to understanding cancerWilliam C Hahn, Ian F Dunn, So Young Kim, et al.
Molecular and Cellular Biology|February 4, 2015
HSP105 recruits protein phosphatase 2A to dephosphorylate β-cateninNancy Yu, Michael Kakunda, Victoria Pham, et al.
Iscience|November 28, 2025
Resource: A compendium of HLA types and expression in pediatric cancer modelsYiwen Guan, Ishika Mahajan, Vikesh Ajith, et al.
The Journal of Biological Chemistry|May 23, 2012
The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanomaYoujun Chen, Cecile Chalouni, Christine Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2011
An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanomaJyoti Asundi, Chae Reed, Jennifer Arca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2015
Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian CancersKedan Lin, Bonnee Rubinfeld, Crystal Zhang, et al.
Cancer Research|February 21, 2012
CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotencyAdam S Adler, Mark L McCleland, Tom Truong, et al.
International Journal of Cancer|October 1, 2009
CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survivalRon Firestein, Kaori Shima, Katsuhiko Nosho, et al.
The Journal of Clinical Investigation|January 12, 2016
CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancerMark L McCleland, Kathryn Mesh, Edward Lorenzana, et al.
Nature Communications|March 18, 2018
PLK1 has tumor-suppressive potential in APC-truncated colon cancer cellsMonika Raab, Mourad Sanhaji, Yves Matthess, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Biochimica Et Biophysica Acta|April 15, 2009
Integrative genomic approaches to understanding cancerWilliam C Hahn, Ian F Dunn, So Young Kim, et al.
Molecular and Cellular Biology|February 4, 2015
HSP105 recruits protein phosphatase 2A to dephosphorylate β-cateninNancy Yu, Michael Kakunda, Victoria Pham, et al.
Iscience|November 28, 2025
Resource: A compendium of HLA types and expression in pediatric cancer modelsYiwen Guan, Ishika Mahajan, Vikesh Ajith, et al.
The Journal of Biological Chemistry|May 23, 2012
The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanomaYoujun Chen, Cecile Chalouni, Christine Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2011
An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanomaJyoti Asundi, Chae Reed, Jennifer Arca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2015
Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian CancersKedan Lin, Bonnee Rubinfeld, Crystal Zhang, et al.
Cancer Research|February 21, 2012
CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotencyAdam S Adler, Mark L McCleland, Tom Truong, et al.
International Journal of Cancer|October 1, 2009
CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survivalRon Firestein, Kaori Shima, Katsuhiko Nosho, et al.
The Journal of Clinical Investigation|January 12, 2016
CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancerMark L McCleland, Kathryn Mesh, Edward Lorenzana, et al.
Nature Communications|March 18, 2018
PLK1 has tumor-suppressive potential in APC-truncated colon cancer cellsMonika Raab, Mourad Sanhaji, Yves Matthess, et al.
Pageof 7